GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Elicio Therapeutics
Elicio, an oncology biotech company, shares reflect the potential of its unique lymph node drug delivery platform. The price trajectory is highly speculative and depends on the results of preclinical and early clinical trials of its immunotherapeutic agents.
Share prices of companies in the market segment - Cancer lymphonodes
Elicio Therapeutics is a biotech company developing lymphotropic immunotherapies for the treatment and prevention of cancer and other diseases. We've categorized it under "Lymph node cancer." The chart below shows how investors view innovative approaches to activating the immune system.
Broad Market Index - GURU.Markets
Elicio Therapeutics is a biotech company developing lymphotropic immunotherapies for the treatment and prevention of cancer and other diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ELTX - Daily change in the company's share price Elicio Therapeutics
Elicio, an oncology company, shares are highly volatile. change_co tracks investor reactions to news about its immunotherapy clinical trials. This metric is the basis for advanced biotech risk analysis formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer lymphonodes
Elicio Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ELTX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Elicio Therapeutics is a biotech company developing lymph node-targeted immunotherapy. Its shares, like many in the sector, are extremely volatile and react to news about clinical trials. These movements are part of the complex landscape of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Elicio Therapeutics
Elicio Therapeutics' year-to-date performance is a story of developing a new generation of cancer vaccines. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its platform, which delivers antigens directly to lymph nodes, could fundamentally improve the effectiveness of immunotherapy.
Annual dynamics of market capitalization of the market segment - Cancer lymphonodes
Elicio Therapeutics, Inc. is a clinical-stage biotech company developing immunotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Elicio Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Elicio Therapeutics
The performance of Elicio, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its innovative cancer vaccines, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Cancer lymphonodes
Elicio Therapeutics develops innovative immunotherapeutics that target lymph nodes to activate a powerful anti-cancer response. The dynamics of the immuno-oncology sector reflect enormous hope for breakthroughs in cancer treatment. Elicio's story is an attempt to prove that its unique approach to "training" the immune system can become a new standard.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Elicio Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing lymph node-targeted immunotherapies for the treatment of cancer and other diseases. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its unique scientific approach impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotech developing immunotherapies for cancer. Its weekly stock price is driven entirely by news of clinical trials of its lymphoma-targeted vaccines, as is typical for this sector.
Weekly dynamics of market capitalization of the market segment - Cancer lymphonodes
Elicio Therapeutics develops lymph node-targeted vaccines and immunotherapies for cancer treatment. This is a disruptive but risky field. The company's shares move in sync with research news. Compare its performance to the sector to see how its scientific ambitions create a unique investment profile.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Elicio is a clinical-stage biotech. Its shares rely on trial news, not macroeconomics. The chart clearly demonstrates how the company's performance is disconnected from the stock market and follows its own scientific calendar.
Market capitalization of the company, segment and market as a whole
ELTX - Market capitalization of the company Elicio Therapeutics
Elicio Therapeutics' market capitalization dynamics reflect investors' faith in its unique platform for developing lympho-targeted cancer immunotherapies. As an early-stage company, its volatile price is driven by news of preclinical and early clinical data. This represents a high-risk bet on a new approach in immuno-oncology.
ELTX - Share of the company's market capitalization Elicio Therapeutics within the market segment - Cancer lymphonodes
Elicio Therapeutics is a biotech company developing a new platform for delivering immunotherapeutic drugs directly to lymph nodes for cancer treatment. Its market share reflects its potential. The graph is a venture bet that its unique approach can significantly enhance the anti-tumor immune response.
Market capitalization of the market segment - Cancer lymphonodes
Here's a chart showing the biotech sector's market capitalization. Elicio Therapeutics is developing a new generation of lymph node-targeted vaccines and immunotherapies. The potential of this market is enormous. Elicio's performance, compared to this market, tells a story of how an innovative delivery platform can dramatically improve the effectiveness of cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Elicio Therapeutics is developing a new cancer immunotherapy platform that targets lymph nodes to generate a stronger immune response. Its market cap is a bet on this innovative approach. The chart below shows the weight of the advanced immuno-oncology sector.
Book value capitalization of the company, segment and market as a whole
ELTX - Book value capitalization of the company Elicio Therapeutics
Elicio Therapeutics' foundation is its Amphiphile scientific platform for developing lymph node-targeted cancer immunotherapy. The book value represents the capital used to conduct clinical trials. The chart tells the story of a biotech company investing in its unique approach to activating the immune system to fight cancer.
ELTX - Share of the company's book capitalization Elicio Therapeutics within the market segment - Cancer lymphonodes
Elicio Therapeutics is developing lymph node-targeted immunotherapy. The chart shows its share of actual R&D assets. These are its laboratories where a unique platform for "training" the immune system to fight cancer is being created.
Market segment balance sheet capitalization - Cancer lymphonodes
Elicio Therapeutics is a biotech company in the R&D stage. Its business is lightweight. The chart below reflects the capital intensity of the entire pharmaceutical sector, which makes its asset-light, science-focused model particularly striking.
Book value of all companies included in the broad market index - GURU.Markets
Elicio Therapeutics is developing a new cancer immunotherapy platform targeting lymph nodes. The company's R&D assets are its own. A modest stake in BCap_All provides the financial basis for an innovative approach that could significantly enhance the anti-tumor immune response.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Elicio Therapeutics
Elicio Therapeutics is an oncology biotech. Its entire market capitalization is a premium to its cash flow. This premium is a bet on its unique platform for delivering immune-boosting agents directly to the lymph nodes.
Market to book capitalization ratio in a market segment - Cancer lymphonodes
Elicio Therapeutics develops immunotherapies for the treatment of cancer and other diseases. Its market cap is based on expectations for its scientific platform. This metric illustrates the significant premium investors are paying for its innovative approach to activating the immune system.
Market to book capitalization ratio for the market as a whole
Elicio Therapeutics is developing a new approach to cancer immunotherapy targeting lymph nodes. The company's entire value lies in its scientific platform. This chart clearly illustrates how market valuation in the biotech sector can be detached from book value, reflecting investor faith in scientific breakthroughs.
Debts of the company, segment and market as a whole
ELTX - Company debts Elicio Therapeutics
Elicio Therapeutics, a biotech developing lymph node-targeted immunotherapy, is financing its innovative platform with leveraged capital. The debt reflects the cost of conducting preclinical and early clinical trials, which are critical to validating its unique approach to cancer treatment.
Market segment debts - Cancer lymphonodes
Elicio Therapeutics is a biotech company developing lymph node-targeted immunotherapy to combat cancer. This innovative approach requires significant investment in R&D. This chart illustrates Elicio's financial model for funding its preclinical and clinical programs to develop new treatments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Elicio Therapeutics
Elicio Therapeutics is developing a lymph node-targeted cancer immunotherapy. Like any biotech company in the R&D stage, it requires ongoing financial infusions. This chart shows its reliance on debt capital to conduct clinical trials, a key factor in assessing its long-term viability.
Market segment debt to market segment book capitalization - Cancer lymphonodes
Elicio Therapeutics develops lymphotropic immunotherapies for the treatment of cancer and other diseases. This chart shows debt trends in the biotech sector. For an early-stage company, this allows it to assess how it finances its innovative drug delivery platform and how its financial model compares to other players in immuno-oncology.
Debt to book value of all companies in the market
Elicio Therapeutics is developing novel immunotherapeutics for the treatment of cancer. Like most research-stage biotech companies, Elicio relies on equity capital to finance its operations. This chart, illustrating the use of debt in the economy, highlights the uniqueness and riskiness of its financial model, which does not involve servicing significant debt.
P/E of the company, segment and market as a whole
P/E - Elicio Therapeutics
Elicio Therapeutics is a biotech company developing a platform for activating the immune system against cancer. This chart does not reflect current revenue, but rather speculative investor expectations for its unique approach. The company's valuation depends entirely on the success of future clinical trials and the potential of its therapeutic vaccines.
P/E of the market segment - Cancer lymphonodes
This industry chart for biotech companies provides key context for Elicio Therapeutics. It reflects overall high valuations based on breakthrough hopes. Comparisons with this chart help understand whether Elicio's unique platform for delivering antigens to lymph nodes to activate the immune response is considered more promising than its competitors.
P/E of the market as a whole
Elicio Therapeutics is developing a cancer immunotherapy that targets lymph nodes to stimulate a powerful response. This is a groundbreaking scientific approach. This chart of overall oncology risk appetite shows whether investors are willing to invest in early-stage companies with breakthrough technologies that haven't yet proven their effectiveness in late-stage trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotech company developing immunotherapies for the treatment of cancer and infectious diseases. This chart shows the speculative expectations for its unique lymph node antigen delivery platform. The valuation depends on the results of clinical trials and the belief that its approach will enhance the body's immune response.
%20P%2FE%20Elicio%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Elicio-Therapeutics&v=1772649113655 "Chart of the company's future (projected) P/E Elicio Therapeutics")
Future (projected) P/E of the market segment - Cancer lymphonodes
Elicio Therapeutics is developing new immunotherapeutic drugs that target lymph nodes to enhance the immune response against cancer. This chart reflects investor expectations for the company's profitability relative to the sector. It provides an insight into the market's confidence in its unique approach to cancer vaccine development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-lymphonodes&v=1772649113680 "Future (projected) P/E graph of the market segment - Cancer lymphonodes")
Future (projected) P/E of the market as a whole
Elicio Therapeutics is developing a platform for delivering immunotherapeutic drugs directly to lymph nodes to combat cancer. For an early-stage biotech like Elicio, this market risk appetite curve is critical. Their success depends on their ability to attract capital for long-term research, which is significantly easier in an optimistic market environment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772649113789 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Elicio Therapeutics
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to lymph nodes to elicit a powerful immune response against cancer. This chart shows the company's financial status during the development phase of this innovative immuno-oncology approach.
Profit of companies in the market segment - Cancer lymphonodes
Elicio Therapeutics is developing lymph node-targeted immunotherapy for cancer treatment. This chart shows the profitability of the oncology sector. For ELTX, this reflects the search for more effective ways to activate the immune system. Their platform aims to "train" immune cells at their "headquarters"—the lymph nodes.
Overall market profit
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to lymph nodes to stimulate a powerful anti-tumor response. This is an innovative approach in oncology. The company's success depends on clinical data. This overall market profitability graph does not reflect the prospects of advanced biotechnologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Elicio Therapeutics
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to lymph nodes to stimulate a powerful anti-cancer response. The revenue projections presented here are speculative and depend on the success of its unique approach in early clinical trials.
%20profit%20of%20the%20company%20Elicio%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Elicio-Therapeutics&v=1772649113949 "Graph of future (projected) profit of the company Elicio Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer lymphonodes
Elicio Therapeutics is developing an immunotherapy that targets lymph nodes to stimulate a potent anti-tumor response. The revenue forecast for this segment depends on the success of this new approach. This chart reflects analysts' belief that innovative ways to activate the immune system could lead to more effective cancer vaccines.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-lymphonodes&v=1772649113958 "Graph of future (predicted) profits of companies in a market segment - Cancer lymphonodes")
Future (predicted) profit of the market as a whole
Elicio Therapeutics develops immunotherapies for the treatment of cancer and infectious diseases. The company's future depends on the success of its clinical programs. The overall market profit forecasts reflected here form the investment backdrop. During growth periods, investors are more inclined to fund risky but promising biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772649113985 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Elicio Therapeutics
Elicio Therapeutics is developing a platform for delivering immunotherapeutic drugs directly to lymph nodes to enhance the anti-cancer immune response. This chart shows a high speculative valuation. Investors are betting on the potential of its unique technology to create more effective vaccines and cancer treatments.
P/S market segment - Cancer lymphonodes
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to lymph nodes to trigger a powerful anti-cancer immune response. This chart shows the average revenue estimate in the biotech sector, helping to understand the high expectations investors have for Elicio's breakthrough technology.
P/S of the market as a whole
Elicio Therapeutics is developing a new generation of vaccines and immunotherapies for cancer treatment using its lympho-targeted Amphiphile platform. The company is in early-stage clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Elicio Therapeutics
Elicio Therapeutics develops innovative immunotherapeutic drugs that target lymph nodes to stimulate a powerful anti-cancer response. This chart shows how the market values the company based on its future revenue potential, reflecting hopes for a new approach to cancer treatment.
%20P%2FS%20Elicio%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Elicio-Therapeutics&v=1772649114048 "The graph of the company's future (projected) P/S Elicio Therapeutics")
Future (projected) P/S of the market segment - Cancer lymphonodes
Elicio Therapeutics is developing a new platform for creating vaccines and immunotherapies that target lymph nodes to stimulate a strong immune response against cancer. This chart reflects investors' confidence in its innovative scientific approach and the potential of its oncology developments.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-lymphonodes&v=1772649114077 "Future (projected) P/S market segment graph - Cancer lymphonodes")
Future (projected) P/S of the market as a whole
Elicio Therapeutics is a biotech company developing immunotherapies for cancer treatment. As a clinical-stage company, it relies entirely on external funding. This market optimism curve is critical for ELTX. Investors' appetite for high-risk biotech projects is directly linked to their belief in overall economic growth and future breakthroughs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772649114119 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company developing a new class of lymph node-targeted immunotherapeutics for cancer treatment. The company currently has no commercial products. This timeline will reflect its ability to successfully commercialize its innovative cancer platform.
Sales of companies in the market segment - Cancer lymphonodes
Elicio Therapeutics is developing an innovative platform for creating immunotherapeutic agents that are delivered directly to the lymph nodes to "train" the immune system to fight cancer. This is a highly precise approach to activating the immune system. While in clinical trials, the company has not yet generated commercial revenue from its products.
Overall market sales
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to lymph nodes to induce a powerful and targeted immune response against cancer. This revenue segment includes the innovative healthcare sector, where ELTX aims to improve the effectiveness of cancer treatments through its unique approach.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Elicio Therapeutics
Elicio Therapeutics develops innovative lymphotropic immunotherapies for cancer treatment. The technology aims to deliver vaccines and other agents directly to the lymph nodes to activate a powerful immune response. This chart reflects analysts' confidence in the potential of this unique platform.
%20sales%20of%20the%20company%20Elicio%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Elicio-Therapeutics&v=1772649114388 "Schedule of future (projected) sales of the company Elicio Therapeutics")
Future (projected) sales of companies in the market segment - Cancer lymphonodes
Elicio Therapeutics is developing a new type of immunotherapy that targets lymph nodes to stimulate a powerful immune response against cancer. This chart shows forecasts for the advanced immuno-oncology market. It illustrates the anticipated emergence of innovative approaches that could significantly improve the immune system's ability to fight tumors.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-lymphonodes&v=1772649114435 "Schedule of future (projected) sales of companies in the market segment - Cancer lymphonodes")
Future (projected) sales of the market as a whole
Elicio Therapeutics, which develops immunotherapy for cancer, sees this chart as a reflection of investor interest in biotech. The stable economic growth predicted here allows investors to fund early-stage companies pursuing breakthrough research. This capital is critical for Elicio's clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772649114476 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Elicio Therapeutics
Elicio Therapeutics is a biotech company developing lymph node-targeted immunotherapy for cancer treatment. Currently in the clinical stage, it is entirely focused on research. This chart does not represent revenue, but rather the investment in its unique scientific platform, which is typical for innovative companies in this industry.
Market segment marginality - Cancer lymphonodes
Elicio Therapeutics is developing a new cancer immunotherapy platform that targets lymph nodes to stimulate a potent immune response. This graph reflects the potential of its technology. Future high operating income will confirm the success of its unique approach to cancer vaccine development.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Elicio Therapeutics
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to the lymph nodes to elicit a powerful and targeted anti-cancer immune response. This graphic shows the team of scientists working on this innovative technology, aiming to significantly improve the effectiveness of vaccines and other cancer treatments.
Share of the company's employees Elicio Therapeutics within the market segment - Cancer lymphonodes
Elicio Therapeutics is developing a new generation of immunotherapies that target lymph nodes to stimulate a powerful anti-cancer response. This cutting-edge technology requires a team of highly skilled immunologists and biochemists. This chart demonstrates the concentration of scientific talent, reflecting the company's position at the forefront of oncology research.
Number of employees in the market segment - Cancer lymphonodes
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to the lymph nodes to trigger a powerful and targeted immune response against cancer. This graphic shows a team of scientists working on an innovative way to "train" the immune system, which could significantly improve the effectiveness of cancer treatment.
Number of employees in the market as a whole
Elicio Therapeutics is a biotech company developing immunotherapies for cancer treatment. Their cutting-edge research requires significant capital investment. The overall economic environment, reflected in the employment chart, provides the backdrop for such investments. A stable labor market and economic growth increase investor risk appetite, which is critical for funding breakthrough oncology research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Elicio Therapeutics (ELTX)
Elicio Therapeutics is a biotech company developing lymph node-targeted immunotherapy. This chart is a pure reflection of their scientific potential. Their astronomical market capitalization per employee indicates the market believes in their unique approach to cancer treatment. The company's value represents the promise of a future blockbuster created by a small team.
%20of%20the%20company%20Elicio%20Therapeutics%20(ELTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Elicio-Therapeutics-ELTX&v=1772649115069 "Chart of market capitalization per employee (in thousands of dollars) of the company Elicio Therapeutics (ELTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer lymphonodes
Elicio Therapeutics develops immunotherapeutic drugs for cancer treatment that target lymph nodes. For a biotech startup, a high valuation per employee reflects investors' faith in its scientific platform. This chart shows the company's market capitalization per employee, allowing for comparison with other oncology players.
%20by%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-lymphonodes&v=1772649115081 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer lymphonodes")
Market capitalization per employee (in thousands of dollars) for the overall market
Elicio Therapeutics is developing a new platform for delivering immunotherapeutic drugs directly to lymph nodes to combat cancer. This biotech milestone reflects the potential of its technology, demonstrating how investors view its innovative approach, which could significantly enhance the immune response against tumors.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772649115092 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Elicio Therapeutics (ELTX)
Elicio Therapeutics is a clinical-stage biotech company developing lymph node-targeted immunotherapy. This graph is negative. The company has no revenue. Its entire scientific staff is dedicated to preclinical and early clinical trials. Each employee is an investment in the creation of a new therapeutic platform.
%20Chart%20Elicio%20Therapeutics%20(ELTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Elicio-Therapeutics-ELTX&v=1772649115144 "Company Profit Per Employee (in thousands of dollars) Chart Elicio Therapeutics (ELTX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer lymphonodes
Elicio Therapeutics is a biotech company developing novel immunotherapeutics for cancer treatment using its lymph node-mediated drug delivery (AMP) platform. This chart shows the industry benchmark for profitability. For Elicio, which is in clinical trials, it demonstrates the economic goal the oncology sector is aiming for if its innovative platforms are successful.
%20in%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-lymphonodes&v=1772649115197 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer lymphonodes")
Profit per employee (in thousands of dollars) for the market as a whole
Elicio Therapeutics is a clinical-stage biotech company. Their unique platform (ELC™) delivers immunotherapeutic drugs (for example, for cancer) directly to the lymph nodes to "train" the immune system. This is R&D. The graph shows the investment (negative return) per scientist working on this targeted delivery technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772649115243 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Elicio Therapeutics (ELTX)
Elicio Therapeutics is developing a platform for delivering immunotherapeutic drugs directly to lymph nodes. This graph illustrates the early stages of biotech innovation. Potentially high revenue per employee in the future will result from licensing the platform or successfully launching its own oncology drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Elicio-Therapeutics-ELTX&v=1772649115259 "Sales chart per company employee Elicio Therapeutics (ELTX)")
Sales per employee in the market segment - Cancer lymphonodes
Elicio Therapeutics is a clinical-stage biotech developing cancer immunotherapies (vaccines). They have no commercial revenue. This chart is typical for R&D companies: it compares their staff of scientists working on future products with zero current revenue, which contrasts sharply with the industry average.
Sales per employee for the market as a whole
Elicio Therapeutics is a biotech company developing a new approach to cancer immunotherapy. Their technology aims to "train" the immune system directly in the lymph nodes. This is pure R&D. This graph will likely show zero revenue, as their team of scientists is still in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Elicio Therapeutics (ELTX)
Elicio Therapeutics (ELTX) is a clinical-stage biotech developing a platform for delivering immunotherapy (including vaccines) to lymph nodes for cancer treatment. This chart shows bearish bets. A high short position is betting against their technology. Investors doubt their approach to "training" the immune system in the lymph nodes will be effective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Elicio-Therapeutics-ELTX&v=1772649115413 "Short Shares Chart for the Company Elicio Therapeutics (ELTX)")
Shares shorted by market segment - Cancer lymphonodes
Elicio (ELTX) is a biotech company developing a platform for delivering immunotherapeutic drugs (including vaccines) directly to lymph nodes. This chart illustrates the general skepticism in the immuno-oncology sector, reflecting investor doubts about the success of this new delivery platform in clinical trials.
Shares shorted by the overall market
Elicio Therapeutics is developing an immunotherapy targeting lymph nodes. It's a research-intensive, early-stage company. When market fear (shown in this chart) is high, investors flee the most speculative assets. Biotech companies without revenue are at the top of this "sell-off" list.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Elicio Therapeutics (ELTX)
Elicio Therapeutics (ELTX) is a biotech company developing immunotherapies (cancer vaccines). Their "EL-AMP" platform targets drug delivery to lymph nodes to activate T cells. This chart measures hype. It shows "overheated" (above 70) due to positive R&D data or "oversold" (below 30) amid delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Elicio-Therapeutics-ELTX&v=1772649115474 "RSI 14 indicator chart for the company's stock Elicio Therapeutics (ELTX)")
RSI 14 Market Segment - Cancer lymphonodes
Elicio (ELTX) is a biotech company developing cancer immunotherapies (vaccines). Their unique approach involves delivering the drug directly to the lymph nodes to "train" T cells. This chart measures overall sentiment in the Oncology sector. It helps distinguish the success of ELTX's technology from general "overheating" or "overselling" in the biotech sector.
RSI 14 for the overall market
Elicio (ELTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ELTX (Elicio Therapeutics)
Elicio Therapeutics is a biotech company developing a new immunotherapy platform that "trains" T cells to deliver drugs directly to lymph nodes. This chart shows the speculative average price target from analysts based on the potential of this approach for cancer treatment.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ELTX-Elicio-Therapeutics&v=1772649115551 "A chart showing analyst consensus forecasts for the expected stock price. ELTX (Elicio Therapeutics)")
The difference between the consensus estimate and the actual stock price ELTX (Elicio Therapeutics)
Elicio Therapeutics is a clinical-stage biotech company. Their signature platform (ELC-100) delivers drugs (immunotherapy) not just into the bloodstream, but specifically to the lymph nodes, where the immune system "trains." This chart reflects analysts' speculative expectations for this unique R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ELTX-Elicio-Therapeutics&v=1772649115572 "A chart showing the difference between the consensus forecast and the actual stock price. ELTX (Elicio Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer lymphonodes
Elicio (ELTX) is a biotech company developing a platform for delivering drugs (vaccines) directly to the lymph nodes to "train" the immune system to attack cancer. This chart shows the general expectations of analysts in the oncology sector. It reflects whether experts believe in the success of this innovative R&D platform.
Analysts' consensus forecast for the overall market share price
Elicio Therapeutics is a biotech company developing a platform (Amphiphile) for delivering immunotherapy (vaccines) directly to lymph nodes to combat cancer. This chart shows the overall risk appetite. For Elicio, an early-stage company with an innovative platform, overall market optimism is critical for funding and clinical proof of concept.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Elicio Therapeutics
Elicio Therapeutics is a biotech company with a unique delivery system. Their platform (Amphiphile) is designed to deliver cancer vaccines and immunotherapies directly to the lymph nodes, where the immune system learns. This chart is a clear indicator of faith in their R&D platform. It reflects the market's assessment of their clinical data and delivery technology.
AKIMA Market Segment Index - Cancer lymphonodes
Elicio Therapeutics develops immunotherapy drugs using its lymphatic platform (Amphiphile) to deliver drugs directly to the lymph nodes to combat cancer. This chart shows the average index for the oncology sector. It helps investors assess how Elicio's innovative approach to immune response compares to the industry average.
The AKIM Index for the overall market
Elicio Therapeutics is a biotech company developing cancer vaccines that target lymph nodes to boost the immune response. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative early-stage scientific play compares to overall economic trends and risk appetite.
